Medtronic plc.

Open: 83.87 Close: 82.24 Change: -1.63

Can you guess what an AI found about Medtronic plc..

This document will help you to evaluate Medtronic plc. without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Medtronic plc. are: Medtronic, plc, stock, year, MDT, report, earnings, …

Concept Map

Semantic Network

Stock Summary

Medtronic plc develops, manufactures, and sells device-based medical therapies. Cardiovascular, medical, surgical, and Neuroscience Portfolio segments offer products for spinal surgeons, neurosurgeons, neurologists, neurologist, pain management.

Today's Summary

Medtronic PLC (MDT) stock is trading at $82.25 as of 3:46 PM on Tuesday, August 8, a drop of -$2.48, or -2.93% from the previous closing price of $84.73. The medical device maker issued a weaker than expected forecast for its next fiscal year. Morgan Stanley raised shares of Medtronics from ‘equal. butUTH Hoodtracking Costa320nos touchdowns stoleLight taking badgeIENT

Today's News

Medtronic plc (mdt) stock price, quote & news - stock analysis. Analyst Consensus: Buy Stock Forecasts. Analyst consensus: Buy stock. Price Target $93.57 (13.78% upside) Medtronic PLC closed $13.36 short of its 52-week high ($95.60), which the company reached on August 19th. The medical device maker issued a weaker than expected forecast for its next fiscal year. Medtronic PLC (MDT) stock is trading at $82.25 as of 3:46 PM on Tuesday, Aug 8, a drop of -$2.48, or -2.93% from the previous closing price of $84.73. Medtronics has made 115 investments. Medtronic plans to report its second, third, and fourth quarter fiscal year 2024 results on Tuesday, November 21, 2023 , Tuesday, February 20, 2024 , and Thursday, May 23, 2024. The Medical Surgical Group is part of Medtronic plc, the global leader in medical technology. Responsible for pursuing leads, assessing needs and providing product services. Medtronic PLCs (MDT) CEO Geoffrey Martha on Q2 2021 Results - Earnings Call Transcript. Nasdaq provides visual representation of analyst expected earnings growth. Medtronic plc (NYSE:MDT) Q3 2023 Earnings Call Transcripts. Fiscal year 2022 Cardiovascular revenue of $11.423 billion increased 6% as reported and 6% organic. Medtronic continues to be an appealing investment proposition for those seeking both capital appreciation and stable yields from dividends. The medical technology company reported earnings per share (EPS) of $1.57 for the quarter ended May 25th. Veeva Systems  VEEV Pfizer PFE Biogen BIIB Gilead Sciences GILD Medtronic  MDT. Morgan Stanley raised shares of Medtronic from an “equal weight” rating to an ‘overweight’ rating. Morgan Stanley set a $104.00 price objective on the stock. Medtronic plc (NYSE: MDT) delivered earnings and revenue surprises of 3.17% and 2.76% for the quarter ended January 2023. The medical device company is expected to post quarterly earnings of $1.57 per share in its upcoming report. This page includes detailed information about the financial performance of Medtronic, including the latest financial reports. The “Microscopes Market” grew its position in shares of Med tronic plc (NYSE:MDT – Get Rating) by 6.7%. Medtronic (MDT) last released its quarterly earnings results on Tuesday, February 21st. EDT), Thursday, May 22. Earnings are expected to decrease by -0.57% in the coming year. Medtronic to announce financial results for its first quarter of fiscal year 2024. Webcast will be available at 7:00 a.m. Central Daylight Time. Axonics challenges to Medtronic device patents revived by U.S. Court of Appeals for the Federal Circuit. Company says it is confident in the strength of our patent portfolio

Stock Profile

"Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland."

Keywords

The game is changing. There is a new strategy to evaluate Medtronic plc. fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Medtronic plc. are: Medtronic, plc, stock, year, MDT, report, earnings, and the most common words in the summary are: medtronic, stock, plc, mdt, earnings, market, year, . One of the sentences in the summary was: Morgan Stanley raised shares of Medtronics from ‘equal. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #medtronic #stock #plc #mdt #earnings #market #year.